Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment

Neoplasma

Volumn 53, Issue 4, 2006, Pages 285-290

  Eriksson, P ^a   Brattstrom D ^a   Hesselius, P ^a   Larsson, A ^a   Bergstrom S ^a   Ekman, S ^a   Goike, H ^b   Wagenius, G ^a   Brodin, O ^c   Bergqvist, M ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b IDL Biotech AB   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; bFGF; Cytokeratins 8, 18, 19; MonoTotal; Non small cell lung cancer; Survival; VEGF

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CISPLATIN; CYTOKERATIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MITOMYCIN C; VASCULOTROPIN;

ARTICLE; BIOASSAY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; FEMALE; FOLLOW UP; FRAGMENTATION REACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MULTIVARIATE ANALYSIS; PATIENT MONITORING;

EID: 33746361476     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. FELD R, GINSBERG RJ, PAYNE DG, SHEPARD FA. Lung. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, editors. Clinical Oncology. Edition Churchill Livingstone 1995: 1083-1152.
2. CHU PG, WEISS LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40: 403-439.
3. SCARPATETTI M, TSYBROVSKYY O, POPPER HH. Cytokeratin typing as an aid in the differential diagnosis of primary versus metastatic lung carcinomas, and comparison with normal lung. Virchows Arch 2002; 440: 70-76.
4. CAI YC, BANNER B, GLICKMAN J, ODZE RD. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol 2001; 32: 1087-1093.
5. BERGQVIST M, BRATTSTROM D, HESSELIUS P et al. Cytokeratin 8 and 18 fragments measured in serum and their relation to survival in patients with non-small cell lung cancer. Anticancer Res 1999; 19: 1833-1836.
6. BUCCHERI G, FERRIGNO D. The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods. Chest 1995; 107: 471-476.
7. BARAK V, GOIKE H, PANARETAKIS KW, EINARSSON R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37: 529-540.
8. KLAGSBRUN M, D'AMORE PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259-270.
9. BATES DO, HILLMAN NJ, WILLIAMS B et al. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002; 200: 581-597.
10. CRONAUER MV, SCHULZ WA, SEIFERT HH et al. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003; 43: 309-319.
11. NAGAI A, TERASHIMA M, HARADA T et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chim Acta 2003; 329: 53-60.
12. THERASSE P. Measuring the clinical response. What does it mean? Eur J Cancer 2002; 38: 1817-1823.
13. STIGBRAND T, ANDRES C, BELLANGER L et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop. Tumour Biol 1998; 19: 132-152.
14. TAMURAM, OHTA Y, KAJITA T et al. Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol Rep 2001; 8: 1097-1102.
15. RIEDEL F, GOTTE K, SCHWALB J et al. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000; 17: 1099-1105.
16. GOSPODAROWICZ D, NEUFELD G, SCHWEIGERER L. Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. Cell Differ 1986; 19: 1-17.
17. BAUER T, MUHRER KH, MULLER H, GREBE SF. Short-term and long-term monitoring of the serum level of TPA after radical resection of gastrointestinal or lung cancer. Nucl Med Commun 1986; 7: 121-127.
18. SILEN A, WESTLIN JE, LETOCHA H, WIKLUND B, EKBLOM J, NILSSON S. Novel monoclonal antibodies reactive with cytokeratins 8 and 18. Immunocytology, Immunohistology and Immunoscintology, Antibody, Immunoconjugates and radiopharmaceuticals 1994; 7: 179-194.
19. PRADIER O, HILLE A, SCHMIBERGER H, HESS CF. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. Cancer Radiother 2002; 6: 15-21.
20. NISMAN B, LAFAIR J, HECHING N et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 1998; 82: 1850-1859.
21. BARLESI F, GIMENEZ C, TORRE JP et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 2004; 98: 357-362.
22. BARLESI F, TCHOUHADJIAN C, DODDOLIC et al. CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer 2005; 92: 13-14.
23. BUCCHERI G, TORCHIO P, FERRIGNO D. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest 2003; 124: 622-632.
24. NIKLINSKI J, BURZYKOWSKI T, NIKLINSKA W et al. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. Eur Respir J 1998; 12: 1424-1428.
25. NISMAN B, AMIR G, LAFAIR J et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999; 19: 3549-3552.
26. PUJOL JL, MOLINIER O, EBERT W et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90: 2097-2105.
27. REINMUTH N, BRANDT B, SEMIK M et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002; 36: 265-270.
28. LINDER C, LINDER S, MUNCK-WIKLAND E, STRANDER H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998; 18: 2063-2068.
29. CHOI JH, KIM HC, LIM HY et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer 2001; 33: 171-179.
30. IMOTO H, OSAKI T, TAGA S et al. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998; 115: 1007-1014.
31. MATSUYAMA W, HASHIGUCHI T, MIZOGUCHI A et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000; 118: 948-951.
32. LAACK E, KOHLER A, KUGLER C et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002; 13: 1550-1557.
33. JOENSUU H, ANTTONEN A, ERIKSSON M et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002; 62: 5210-5217.
34. BRATTSTROM D, BERGQVIST M, HESSELIUS P et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002; 37: 57-63.
35. UENO K, INOUE Y, KAWAGUCHI T et al. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001; 31: 213-219.
36. YLISIRNIO S, HOYHTYA M, MAKITARO R et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001; 7: 1633-1637.